Introduction
An outbreak of diarrhoea occurred at a 637 bed psychiatric hospital in south east England on 11-14 June 1989. Fifty elderly residents were affected and two died. The source of the outbreak was identified. At the inquest the coroner and the press concentrated on the state of the kitchens, as outlined in the environmental health officer's report. During the course of the inquiry, however, several other problems came to light, including lapses in medical care but, above all, underlying difficulties within the catering department.
The organism causing the outbreak was identified as Clostridium perfringens type A. The source was established epidemiologically, by food questionnaire, as a minced beef meal served at lunchtime on 11 June. The outbreak was confined to patients in only four of the 16 wards that had received the meal, and this was thought to be related to division of the minced beef at a late stage in food preparation. The How will ancillary workers fare in the light of the NHS review? They wield little power and lack the voice of the professions. Union representation has at least guaranteed minimum rights, but the combined deregulation of national pay scales and the proposed removal of union representatives from health authorities will probably mean greater exploitation. This may result ultimately in a climate of discontent, even lower morale, and fragmentation of health care. ' The experience of ancillary workers has implications for all staff within the NHS. Will the rights of staff to reasonable terms and conditions of service be maintained? Will quality be made subservient to the goal of cost reduction and income generation? Will quality of care suffer? What guarantees do we have as we prepare to enter the market place that provider and consumer will both benefit from the caring institution we know as the NHS? 
ANY QUESTIONS
A woman in her 50s has had surgerv for carcinoma of the breast. She had been receiving oestrogen replacement treatment for six months before the operation and wants to continue with it. Must she stop taking it, and if not can she take tamoxifen as well?
The long established view that the use of hormone replacement treatment is contraindicated in patients with primary breast cancer because oestrogen stimulates breast tissue has recently been modified. Epidemiological studies have confirmed that such treatment does not increase the incidence of breast cancer.' If this patient is to continue with the treatment it must be a combination of oestrogen with progestogen. The question implies that she was receiving oestrogen replacement alone, which might well have been prescribed if she had had a hysterectomy. Progestogen is added to oestrogen in standard hormone replacement treatment to counteract its effect on the endometrium, which if unopposed by progestogen leads to endometrial hyperplasia or cancer. Progestogen has the same effect on breast tissue, counteracting the mitotic action of oestrogen by diverting the cells from proliferation to differentiation. It is therefore considered safe to continue this patient's low dose combination hormone replacement treatment after breast surgery for a limited period of six months to a year provided that her menopausal symptoms for which the treatment was prescribed are sufficiently severe to justify treatment. Hormone replacement treatment is prescribed not only to alleviate menopausal symptoms but to protect against osteoporosis and cardiovascular disease long term. The question arises, therefore, whether long term combination treatment over a period of 10 years is advisable.
I would advise against prescribing long term combination hormone replacement treatment in patients who were found to have lymph node disease and oestrogen receptors at the time of the breast surgery. I would recommend long term combination treatment with careful follow up for patients without node disease or oestrogen receptors. There is some evidence that long term combination treatment might be beneficial in patients with advanced breast cancer.' This is presumably due to the progestogen component, which can be given alone as Provera. Tamoxifen Are mercurv vapour lamps hazardous to eyesight?
There is little evidence that mercury vapour lamps in themselves can cause damage to the eye. The bluish white light that they produce provides good visibility and prevents traffic accidents. The hazard that they may pose to human eyes and skin has caused the Food and Drug Administration in the United States to establish new protective standards. The danger is related to breakage of an outer glass shield, allowing the inner tube containing the mercury gas to irradiate the eyes with ultraviolet light. Eye injuries may occur to someone standing about 9 m from the broken lamp. 
